CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
22. Juni 2022 08:00 ET
|
CymaBay Therapeutics, Inc.
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a...
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022
08. Juni 2022 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
23. Mai 2022 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
12. Mai 2022 16:06 ET
|
CymaBay Therapeutics, Inc.
Over 150 clinical sites now activated in RESPONSE Phase 3 clinical trial Results from a 52-week, open-label phase 2 study of seladelpar in patients with PBC published in the Journal of Hepatology ...
CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
11. Mai 2022 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022
05. Mai 2022 16:01 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
04. April 2022 08:00 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
17. März 2022 16:25 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update
17. März 2022 16:06 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022
10. März 2022 16:05 ET
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...